Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2017; 8(11):2104-2113. doi:10.7150/jca.19078 This issue Cite

Research Paper

CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma

Huzheng Yan#, Zhiqiang Mo#, Zhanwang Xiang#, Dailin Rong#, Yanlin Zhang, Guanyu Chen, Zhihui Zhong, Fujun Zhang✉, Fei Gao✉

Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. ADD: 651 Dongfeng Road, East, Guangzhou, China.
#These authors contributed equally to this work.

✉ Corresponding authors: Fujun Zhang, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. ADD: 651 Dongfeng Road, East, Guangzhou, China. More

Citation:
Yan H, Mo Z, Xiang Z, Rong D, Zhang Y, Chen G, Zhong Z, Zhang F, Gao F. CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J Cancer 2017; 8(11):2104-2113. doi:10.7150/jca.19078. https://www.jcancer.org/v08p2104.htm
Other styles

File import instruction

Abstract

Purpose: The study evaluated the feasibility, clinical effectiveness, and quality of life of computed tomography (CT)-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma (NPC).

Methods: We recruited 81 patients diagnosed with locally recurrent NPC after previous radiotherapy with or without chemotherapy. Thirty-nine patients received 125I brachytherapy (group A) and 42 received re-irradiation (IMRT, group B). The evaluated outcomes were local control, complications, and quality of life. Cox proportional hazards regression analysis was used to compare local tumor progression-free survival (LTPFS) and overall survival (OS) in the two treatment groups.

Results: The median follow-up was 30 months (range, 5-68 months), median LTPFS was 21 in group A and 17 months in group B. The 1-, 2-, and 3-year OS in group A were 84.6%, 51.3%, 30.7%, and 85.7%, 50.0%, and 32.6% in group B. In group A, 10/39 patients (25.6%) experienced at least one ≥grade III complication; no grade V complications occurred. In group B, 28/42 (66.7%) experienced at least one ≥grade III complication and 6/42 (14.3%) died of severe grade V complications. No significant between-group difference existed in the Quality of Life score on the EORTC QLQ-H&N35 questionnaire before treatment. In group A, quality of life was significantly improved after treatment; but did not improve, or even deteriorated in group B.

Conclusions: 125I brachytherapy was a feasible, safe, and effective treatment for locally recurrent NPC. 125I brachytherapy significantly reduced complications caused by re-irradiation and improved patients' quality of life.

Keywords: 125I brachytherapy, 125I seeds, recurrent nasopharyngeal carcinoma, quality of life, complications, local control

Citation styles

APA
Yan, H., Mo, Z., Xiang, Z., Rong, D., Zhang, Y., Chen, G., Zhong, Z., Zhang, F., Gao, F. (2017). CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. Journal of Cancer, 8(11), 2104-2113. https://doi.org/10.7150/jca.19078.

ACS
Yan, H.; Mo, Z.; Xiang, Z.; Rong, D.; Zhang, Y.; Chen, G.; Zhong, Z.; Zhang, F.; Gao, F. CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J. Cancer 2017, 8 (11), 2104-2113. DOI: 10.7150/jca.19078.

NLM
Yan H, Mo Z, Xiang Z, Rong D, Zhang Y, Chen G, Zhong Z, Zhang F, Gao F. CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J Cancer 2017; 8(11):2104-2113. doi:10.7150/jca.19078. https://www.jcancer.org/v08p2104.htm

CSE
Yan H, Mo Z, Xiang Z, Rong D, Zhang Y, Chen G, Zhong Z, Zhang F, Gao F. 2017. CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma. J Cancer. 8(11):2104-2113.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use